US Patent Issued to Memorial Sloan Kettering Cancer Center on July 1 for "Inflammasome-targeted RNA interference approach to treating kidney injury and disease" (New York Inventors)

ALEXANDRIA, Va., July 3 -- United States Patent no. 12,343,407, issued on July 1, was assigned to Memorial Sloan Kettering Cancer Center (New York).

"Inflammasome-targeted RNA interference approach to treating kidney injury and disease" was invented by Michael R. McDevitt (New York) and David A. Scheinberg (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure relates generally to methods for treating, preventing, and/or ameliorating chronic kidney disease (CKD) and/or renal injury in a subject in need thereof. In particular, the methods disclosed herein comprise administering a therapeutically effective amount of a pharmaceutical composition comprising at least one Nlrp3 siRNA non-c...